Kuros Biosciences, Arbutus Biopharma deal

Arbutus terminated a deal with Kuros, returning to Kuros worldwide rights to its virus-like particle (VLP) platform. Arbutus said it terminated the deal because preclinical data for ARB-1598 did not ...